Pretransplant CMV-Specific T-Cell Immunity But Not Dose of Antithymocyte Globulin Is Associated With Recovery of Specific Immunity After Kidney Transplantation

Background. This is a prospective, multicenter, observational study in cytomegalovirus (CMV)-seropositive kidney transplant recipients with pretransplant CMV-specific cell-mediated immunity (CMV-CMI) receiving antithymocyte globulin (ATG). We aimed to investigate posttransplant CMV-CMI over time and...

ver descrição completa

Detalhes bibliográficos
Autores: Paez-Vega, A, Cantisan, S, Aguera, ML, Suner, M, Facundo, C, Yuste, JR, Fernandez-Ruiz, M, Montejo, M, Redondo-Pachon, D, Lopez-Oliva, MO, Fernandez-Rodriguez, A, Farinas, MC, Hernandez, D, Len, O, Munoz, P, Valle-Arroyo, J, Rodelo-Haad, C, Cordero, E, Torre-Cisneros, J
Tipo de documento: artigo
Estado:Versão publicada
Data de publicação:2021
País:España
Recursos:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
Repositório:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
OAI Identifier:oai:iibsantpau.fundanetsuite.com:p4851
Acesso em linha:https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4851
http://hdl.handle.net/10902/24486
Access Level:Acceso aberto
Palavra-chave:cytomegalovirus infection
kidney transplant
kinetics of CMV-specific cell-mediated immunity
QuantiFERON-CMV assay
antithymocyte globulin
id ES_4bbd136cdc008daeb1f664e2f48bff1f
oai_identifier_str oai:iibsantpau.fundanetsuite.com:p4851
network_acronym_str ES
network_name_str España
repository_id_str
spelling Pretransplant CMV-Specific T-Cell Immunity But Not Dose of Antithymocyte Globulin Is Associated With Recovery of Specific Immunity After Kidney TransplantationPaez-Vega, ACantisan, SAguera, MLSuner, MFacundo, CYuste, JRFernandez-Ruiz, MMontejo, MRedondo-Pachon, DLopez-Oliva, MOFernandez-Rodriguez, AFarinas, MCHernandez, DLen, OMunoz, PValle-Arroyo, JRodelo-Haad, CCordero, ETorre-Cisneros, Jcytomegalovirus infectionkidney transplantkinetics of CMV-specific cell-mediated immunityQuantiFERON-CMV assayantithymocyte globulinBackground. This is a prospective, multicenter, observational study in cytomegalovirus (CMV)-seropositive kidney transplant recipients with pretransplant CMV-specific cell-mediated immunity (CMV-CMI) receiving antithymocyte globulin (ATG). We aimed to investigate posttransplant CMV-CMI over time and the impact of the dose-dependent ATG. Methods. CMV-CMI was assessed at days +30, +45, +60, and +90 after transplantation with the QuantiFERON-CMV assay. A reactive result (interferon-gamma [IFN-gamma] >= 0.2 IU/mL) indicated a positive CMV-CMI. Results. A total of 78 positive CMV-CMI patients were enrolled in the study, of which 59.5% had a positive CMV-CMI at day +30 and 82.7% at day +90. Multivariate logistic regression analysis showed that ATG dose was not associated with positive CMV-CMI at any point. However, pretransplant IFN-gamma level (>12 IU/mL vs <= 12 IU/mL) was associated with positive CMV-CMI at day +30 (odds ratio, 12.9; 95% confidence interval, 3.1-53.3; P <.001). In addition, all the patients who did not recover CMV-CMI at day +90 had a pretransplant IFN-gamma level <= 12 IU/mL. Conclusions. More than half of CMV-seropositive kidney transplant recipients receiving ATG recover (or maintain) CMV-CMI by the first month after transplantation. The pretransplant IFN-gamma level, but not the ATG dose, shows a strong association with the kinetics of this recovery.OXFORD UNIV PRESS INC2021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4851http://hdl.handle.net/10902/24486JOURNAL OF INFECTIOUS DISEASESISSN: 00221899ISSNe: 15376613reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pauinstname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)Inglésinfo:eu-repo/semantics/openAccessoai:iibsantpau.fundanetsuite.com:p48512026-06-14T12:41:47Z
dc.title.none.fl_str_mv Pretransplant CMV-Specific T-Cell Immunity But Not Dose of Antithymocyte Globulin Is Associated With Recovery of Specific Immunity After Kidney Transplantation
title Pretransplant CMV-Specific T-Cell Immunity But Not Dose of Antithymocyte Globulin Is Associated With Recovery of Specific Immunity After Kidney Transplantation
spellingShingle Pretransplant CMV-Specific T-Cell Immunity But Not Dose of Antithymocyte Globulin Is Associated With Recovery of Specific Immunity After Kidney Transplantation
Paez-Vega, A
cytomegalovirus infection
kidney transplant
kinetics of CMV-specific cell-mediated immunity
QuantiFERON-CMV assay
antithymocyte globulin
title_short Pretransplant CMV-Specific T-Cell Immunity But Not Dose of Antithymocyte Globulin Is Associated With Recovery of Specific Immunity After Kidney Transplantation
title_full Pretransplant CMV-Specific T-Cell Immunity But Not Dose of Antithymocyte Globulin Is Associated With Recovery of Specific Immunity After Kidney Transplantation
title_fullStr Pretransplant CMV-Specific T-Cell Immunity But Not Dose of Antithymocyte Globulin Is Associated With Recovery of Specific Immunity After Kidney Transplantation
title_full_unstemmed Pretransplant CMV-Specific T-Cell Immunity But Not Dose of Antithymocyte Globulin Is Associated With Recovery of Specific Immunity After Kidney Transplantation
title_sort Pretransplant CMV-Specific T-Cell Immunity But Not Dose of Antithymocyte Globulin Is Associated With Recovery of Specific Immunity After Kidney Transplantation
dc.creator.none.fl_str_mv Paez-Vega, A
Cantisan, S
Aguera, ML
Suner, M
Facundo, C
Yuste, JR
Fernandez-Ruiz, M
Montejo, M
Redondo-Pachon, D
Lopez-Oliva, MO
Fernandez-Rodriguez, A
Farinas, MC
Hernandez, D
Len, O
Munoz, P
Valle-Arroyo, J
Rodelo-Haad, C
Cordero, E
Torre-Cisneros, J
author Paez-Vega, A
author_facet Paez-Vega, A
Cantisan, S
Aguera, ML
Suner, M
Facundo, C
Yuste, JR
Fernandez-Ruiz, M
Montejo, M
Redondo-Pachon, D
Lopez-Oliva, MO
Fernandez-Rodriguez, A
Farinas, MC
Hernandez, D
Len, O
Munoz, P
Valle-Arroyo, J
Rodelo-Haad, C
Cordero, E
Torre-Cisneros, J
author_role author
author2 Cantisan, S
Aguera, ML
Suner, M
Facundo, C
Yuste, JR
Fernandez-Ruiz, M
Montejo, M
Redondo-Pachon, D
Lopez-Oliva, MO
Fernandez-Rodriguez, A
Farinas, MC
Hernandez, D
Len, O
Munoz, P
Valle-Arroyo, J
Rodelo-Haad, C
Cordero, E
Torre-Cisneros, J
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv cytomegalovirus infection
kidney transplant
kinetics of CMV-specific cell-mediated immunity
QuantiFERON-CMV assay
antithymocyte globulin
topic cytomegalovirus infection
kidney transplant
kinetics of CMV-specific cell-mediated immunity
QuantiFERON-CMV assay
antithymocyte globulin
description Background. This is a prospective, multicenter, observational study in cytomegalovirus (CMV)-seropositive kidney transplant recipients with pretransplant CMV-specific cell-mediated immunity (CMV-CMI) receiving antithymocyte globulin (ATG). We aimed to investigate posttransplant CMV-CMI over time and the impact of the dose-dependent ATG. Methods. CMV-CMI was assessed at days +30, +45, +60, and +90 after transplantation with the QuantiFERON-CMV assay. A reactive result (interferon-gamma [IFN-gamma] >= 0.2 IU/mL) indicated a positive CMV-CMI. Results. A total of 78 positive CMV-CMI patients were enrolled in the study, of which 59.5% had a positive CMV-CMI at day +30 and 82.7% at day +90. Multivariate logistic regression analysis showed that ATG dose was not associated with positive CMV-CMI at any point. However, pretransplant IFN-gamma level (>12 IU/mL vs <= 12 IU/mL) was associated with positive CMV-CMI at day +30 (odds ratio, 12.9; 95% confidence interval, 3.1-53.3; P <.001). In addition, all the patients who did not recover CMV-CMI at day +90 had a pretransplant IFN-gamma level <= 12 IU/mL. Conclusions. More than half of CMV-seropositive kidney transplant recipients receiving ATG recover (or maintain) CMV-CMI by the first month after transplantation. The pretransplant IFN-gamma level, but not the ATG dose, shows a strong association with the kinetics of this recovery.
publishDate 2021
dc.date.none.fl_str_mv 2021
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4851
http://hdl.handle.net/10902/24486
url https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4851
http://hdl.handle.net/10902/24486
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv OXFORD UNIV PRESS INC
publisher.none.fl_str_mv OXFORD UNIV PRESS INC
dc.source.none.fl_str_mv JOURNAL OF INFECTIOUS DISEASES
ISSN: 00221899
ISSNe: 15376613
reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
instname_str Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
reponame_str r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
collection r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869407581972201472
score 15.811543

Registros relacionados